Lexeo Therapeutics, Inc. (LXEO)
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $654.0K
- Net income
- -$100.0M
- Total assets
- $268.7M
- Market cap
- $343.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $109.3M
- Operating income
- -$109.3M
- Income tax
- $0
- Net income
- -$100.0M
- EPS (basic)
- $-1.86
- EPS (diluted)
- $-1.86
Balance sheet
- Total assets
- $268.7M
- Current assets
- $188.4M
- Total liabilities
- $22.0M
- Current liabilities
- $16.8M
- Shareholders’ equity
- $246.7M
Cash flow
- Operating cash flow
- -$98.6M
- Investing cash flow
- -$90.3M
- Financing cash flow
- $216.8M
- Net cash flow
- $28.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $343.1M
- EPS (diluted)
- $-1.86
- Shares outstanding
- 73.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 3, 2023
Lexeo Therapeutics, Inc. (LXEO) Stock Price
- Reported a net loss of $100.0M in FY2022.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lexeo Therapeutics, Inc..
Write a review
News about Lexeo Therapeutics, Inc.
News & sentiment via Polygon.io
Lexeo Therapeutics, Inc.: frequently asked questions
Is Lexeo Therapeutics, Inc. an American company?
Lexeo Therapeutics, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Lexeo Therapeutics, Inc. headquartered?
Lexeo Therapeutics, Inc. is headquartered in New York, New York, United States.
Is Lexeo Therapeutics, Inc. publicly traded?
Yes — Lexeo Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol LXEO on the NASDAQ.
What does Lexeo Therapeutics, Inc. do?
Lexeo Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
